Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates through 3years for adalimumab-treated patients with early Crohn's disease

Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn’s disease

(2011) M. A. Kamm et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn’s disease

(2010) S. B. Hanauer et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn’s disease

(2010) R. PANACCIONE et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Increased Response and Remission Rates in Short-Duration Crohn's Disease With Subcutaneous Certolizumab Pegol: An Analysis of PRECiSE 2 Randomized Maintenance Trial Data

(2010) Stefan Schreiber et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

S1030 Predictors of Response and Remission to Certolizumab Pegol in Patients With Crohn's Disease: Data From the WELCOME Study

(2010) William J. Sandborn et al.   GASTROENTEROLOGY

Risk Factors Associated With Progression to Intestinal Complications of Crohn's Disease in a Population-Based Cohort

(2010) Kelvin T. Thia et al.   GASTROENTEROLOGY

Early Crohn disease: a proposed definition for use in disease-modification trials

(2010) L. Peyrin-Biroulet et al.   GUT

Development of the Crohnʼs disease digestive damage score, the Lémann score

(2010) Benjamin Pariente et al.   INFLAMMATORY BOWEL DISEASES

The potential for disease modification in Crohn's disease

(2010) G. Van Assche et al.   Nature Reviews Gastroenterology & Hepatology

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

(2010) Jean Frédéric Colombel et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Natural History of Adult Crohn's Disease in Population-Based Cohorts

(2009) Laurent Peyrin-Biroulet et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohnʼs disease

(2009) Geert R. DʼHaens et al.   INFLAMMATORY BOWEL DISEASES

Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort

(2008) F Schnitzler et al.   GUT

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial

(2008) Geert D'Haens et al.   LANCET